Study identifies distinct outcomes and genomic features in NSCLC with class II and III BRAF alterations
Patients with metastatic non-small cell lung cancer (NSCLC) harboring class II and class III BRAF alterations have distinct clinicopathologic and genomic characteristics, with class III alterations potentially ...
15 Sep 14:40 · Medical Xpress